Bardoxolone, an Nrf2 activator, has been shown to improve renal functions in type 2 diabetic patients with chronic kidney disease in a human phase 2 trial [38], though it had cardiovascular safety issues [39]. This evidence concerns the gene NFE2L2 and chronic kidney disease.